NASDAQ:IBBiShares Nasdaq Biotechnology ETF Stock Price, Forecast & News

iShares Nasdaq Biotechnology ETF's stock was trading at $106.97 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IBB stock has increased by 28.4% and is now trading at $137.37. View which stocks have been most impacted by Coronavirus.

iShares Nasdaq Biotechnology ETF announced a quarterly dividend on Wednesday, March 25th. Shareholders of record on Thursday, March 26th will be given a dividend of $0.0554 per share on Tuesday, March 31st. This represents a $0.22 dividend on an annualized basis and a dividend yield of 0.16%. The ex-dividend date of this dividend is Wednesday, March 25th. View iShares Nasdaq Biotechnology ETF's dividend history.

Shares of iShares Nasdaq Biotechnology ETF split before market open on Friday, December 1st 2017. The 3-1 split was announced on Tuesday, November 7th 2017. The newly minted shares were payable to shareholders after the closing bell on Thursday, November 30th 2017. An investor that had 100 shares of iShares Nasdaq Biotechnology ETF stock prior to the split would have 300 shares after the split.

News articles about IBB stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. iShares Nasdaq Biotechnology ETF earned a coverage optimism score of -1.0 on InfoTrie's scale. They also gave news headlines about the financial services provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about iShares Nasdaq Biotechnology ETF.

Some companies that are related to iShares Nasdaq Biotechnology ETF include DNP Select Income Fund (DNP), Nuveen Municipal Value Fund (NUV), Adams Diversified Equity Fund (ADX), PIMCO Corporate&Income Opportunity Fund (PTY), Tri-Continental (TY), Gabelli Equity Trust (GAB), Royce Value Trust (RVT), Liberty All-Star Equity Fund (USA), Hercules Capital (HTGC), Boulder Growth & Income Fund (BIF), Tekla Healthcare Investors (HQH), Blackrock Muniyield Insured Fund (MYI), AllianceBernstein Global Hgh Incm Fd (AWF), Tortoise Energy Infrastructure (TYG) and Invesco Van Kampen Munpl Oprtnty Tr (VMO). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other iShares Nasdaq Biotechnology ETF investors own include NVIDIA (NVDA), Alibaba Group (BABA), Walt Disney (DIS), Netflix (NFLX), Bank of America (BAC), Tesla (TSLA), Cisco Systems (CSCO), Gilead Sciences (GILD), Micron Technology (MU) and Boeing (BA).

iShares Nasdaq Biotechnology ETF trades on the NASDAQ under the ticker symbol "IBB."

iShares Nasdaq Biotechnology ETF's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include M&R Capital Management Inc. (0.05%).

IBB stock was acquired by a variety of institutional investors in the last quarter, including M&R Capital Management Inc..

Shares of IBB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IBB stock can currently be purchased for approximately $137.37.

iShares Nasdaq Biotechnology ETF has a market capitalization of $9.56 billion.